Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10815346 | 0.83 | KMT2A (0.33) | SMN1; SMN2MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL22028162 | 0.82 | KMT2A (0.36) | SMN1; SMN2MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL20189667 | 0.82 | KMT2A (0.36) | SMN1; SMN2MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL8216998 | 0.80 | EPHX1 (0.33) | L3MBTL1SMN1; SMN2HSD17B10ALDH1A1LMNA | |
| SCHEMBL1979548 | 0.73 | SMN1; SMN2 (0.38) | L3MBTL1SMN1; SMN2HSD17B10ALDH1A1TSHR | |
| SCHEMBL6729276 | 0.73 | SMN1; SMN2 (0.38) | SMN1; SMN2HSD17B10ALDH1A1TSHRCYP2D6 | |
| SCHEMBL927792 | 0.72 | SMN1; SMN2 (0.34) | SMN1; SMN2HSD17B10ALDH1A1TSHRCYP2D6 | |
| SCHEMBL23813395 | 0.72 | — | — | |
| SCHEMBL2044485 | 0.71 | KDM4E (0.48) | MEN1KMT2AALDH1A1TSHRCYP2D6 | |
| SCHEMBL6730282 | 0.71 | ALDH1A1 (0.38) | SMN1; SMN2HSD17B10MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2083844-B1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2013-11-27 | — | — | EP | disclosed |
| US-8377874-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20100286185-A1 | HCV NS3 Protease Inhibitors | MERCK SHARP & DOHME LLC | 2010-11-11 | — | — | US | disclosed |
| EP-2083844-A2 | HCV NS3 PROTEASE INHIBITORS | Merck & Co., Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008057208-A2 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286185-A1 | HCV NS3 Protease Inhibitors | HAVCR2, GTF3C3, CTSC | L3MBTL1 2610/4885SMN1; SMN2 4284/4885HSD17B10 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.